NCT00241670View on ClinicalTrials.gov

Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid

PHASE3CompletedINTERVENTIONAL
Enrollment

415

Participants

Timeline

Start Date

October 31, 1999

Primary Completion Date

July 31, 2004

Conditions
Brain CancerBrain TumorsCancer of BrainPrimary Brain TumorsBrain Tumor, Primary
Interventions
DRUG

5-aminolevulinic acid (5-ALA)

1.5 grams 5-ALA dissolved in 50 ml water, single dose, orally, 2-4 hours prior to surgery

All Listed Sponsors
lead

medac GmbH

INDUSTRY

NCT00241670 - Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid | Biotech Hunter | Biotech Hunter